NEUP on Nasdaq
Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc. is a Delaware corporation and a clinical-stage biotechnology company.4 From its latest annual report
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Bioline Rx Ltd., ALX ONCOLOGY HOLDINGS INC or Longeveron Inc., or pick any stock.
- TickerNEUP on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersBurlington, Massachusetts1
- Incorporated inAustralia3
- Business address100 Summit Dr, Burlington, Ma 018033
- Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company3
See how the biggest companies compare on our leaderboards
Neuphoria Therapeutics Inc. is a Delaware corporation and a clinical-stage biotechnology company. Following the results of our Phase 3 AFFIRM-1 trial and the restructuring actions taken during fiscal 2026, our activities are focused on completing the proposed merger with Scancell Holdings plc ("Scancell"), preserving cash, maintaining our public-company and contractual obligations, and managing our intellectual property and economic interests in partnered programs. We are currently conducting limited active internal research and development activities focused on our alpha7 nicotinic acetylcholine receptor negative allosteric modulator portfolio.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
Where the money goes
Where each dollar of revenue went, fiscal 2026
- Other costs88¢$1.0M
- Income tax12¢$139.2K
Out of $1.2M in revenue.2 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-06-30 | 2025-06-30 |
|---|---|---|
| Total revenue | $1.2M | $15.6M |
| Research and development | $3.5M | $9.0M |
| General and administrative | $7.4M | $7.8M |
| Restructuring costs | $1.3M | |
| Goodwill impairment | $5.4M | |
| Total operating expenses | $17.6M | $16.8M |
| Loss from operations | -$16.5M | -$1.1M |
| Interest income, net | $665.6K | $166.5K |
| Loss on foreign currency transactions | -$535.7K | -$415.0K |
| Research and development incentive award | $800.9K | $299.9K |
| Gain on fair value adjustments | $1.9M | $239.7K |
| Total other income | $2.9M | $291.1K |
| Loss before income taxes | -$13.6M | -$838.0K |
| Income tax benefit | $139.2K | $468.4K |
| Net loss | -$13.5M | -$369.6K |
| Unrealized gain on foreign currency translation | $781.9K | $168.5K |
| Total other comprehensive income | $781.9K | $168.5K |
| Comprehensive loss | -$12.7M | -$201.1K |
| Net loss per share - basic | -$3.06 | -$0.23 |
| Net loss per share - diluted | -$3.06 | -$0.23 |
| Weighted-average common shares outstanding - basic | 4.4M shares | 1.6M shares |
| Weighted-average common shares outstanding - diluted | 4.4M shares | 1.6M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2026-06-30 | 2025-10-31 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | $19.9M | $14.2M | ||
| Accounts receivable, non-trade | $813.4K | $11.9K | ||
| Restricted cash | $77.9K | |||
| Prepaid expenses | $389.8K | $740.2K | ||
| Total current assets | $21.1M | $15.0M | ||
| Property and equipment, net | $2.8K | |||
| Intangible assets, net | $4.1M | $4.8M | ||
| Operating lease right-of-use assets | $102.6K | |||
| Goodwill | $3.5M | $8.6M | $8.7M | |
| Total assets | $28.7M | $28.6M | ||
| Accounts payable | $385.6K | $1.2M | ||
| Accrued expenses and other current liabilities | $371.0K | $3.0M | ||
| Operating lease liability | $116.3K | |||
| Total current liabilities | $756.6K | $4.2M | ||
| Contingent consideration | $1.0M | $1.2M | ||
| Deferred tax liability | $355.9K | $495.1K | ||
| Accompanying warrant liability | $2.0M | $3.7M | ||
| Total liabilities | $4.1M | $9.6M | ||
| Common stock, $0.00001 par value, 5,411,334 and 1,978,460 shares issued and outstanding at June 30, 2026 and 2025, respectively | $54 | $19 | ||
| Additional paid in capital, net of subscription receivable | $218.5M | $200.2M | ||
| Accumulated other comprehensive loss, net of tax | -$2.1M | -$2.8M | ||
| Accumulated deficit | -$191.8M | -$178.3M | ||
| Total shareholders equity | $24.6M | $19.0M | $17.5M | |
| Total liabilities and shareholders equity | $28.7M | $28.6M | ||
| Common stock, par value | $0.00 | $0.00 | $0.00 | |
| Common stock, shares issued | 5.4M shares | 2.0M shares | ||
| Common stock, shares outstanding | 5.4M shares | 2.0M shares |
| Period ending | 2026-06-30 | 2025-10-31 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | $19.9M | $14.2M | ||
| Accounts receivable, non-trade | $813.4K | $11.9K | ||
| Restricted cash | $77.9K | |||
| Prepaid expenses | $389.8K | $740.2K | ||
| Total current assets | $21.1M | $15.0M | ||
| Property and equipment, net | $2.8K | |||
| Intangible assets, net | $4.1M | $4.8M | ||
| Operating lease right-of-use assets | $102.6K | |||
| Goodwill | $3.5M | $8.6M | $8.7M | |
| Total assets | $28.7M | $28.6M | ||
| Accounts payable | $385.6K | $1.2M | ||
| Accrued expenses and other current liabilities | $371.0K | $3.0M | ||
| Operating lease liability | $116.3K | |||
| Total current liabilities | $756.6K | $4.2M | ||
| Contingent consideration | $1.0M | $1.2M | ||
| Deferred tax liability | $355.9K | $495.1K | ||
| Accompanying warrant liability | $2.0M | $3.7M | ||
| Total liabilities | $4.1M | $9.6M | ||
| Common stock, $0.00001 par value, 5,411,334 and 1,978,460 shares issued and outstanding at June 30, 2026 and 2025, respectively | $54 | $19 | ||
| Additional paid in capital, net of subscription receivable | $218.5M | $200.2M | ||
| Accumulated other comprehensive loss, net of tax | -$2.1M | -$2.8M | ||
| Accumulated deficit | -$191.8M | -$178.3M | ||
| Total shareholders equity | $24.6M | $19.0M | $17.5M | |
| Total liabilities and shareholders equity | $28.7M | $28.6M | ||
| Common stock, par value | $0.00 | $0.00 | $0.00 | |
| Common stock, shares issued | 5.4M shares | 2.0M shares | ||
| Common stock, shares outstanding | 5.4M shares | 2.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-06-30 | 2025-06-30 |
|---|---|---|
| Net loss | -$13.5M | -$369.6K |
| Share-based compensation | $351.6K | $163.8K |
| Goodwill impairment | $5.4M | |
| Depreciation and amortization expense | $663.0K | $662.9K |
| Non-cash rent expense | $102.6K | $114.4K |
| Change in fair value of accompanying warrant liability | -$1.7M | -$956.3K |
| Change in fair value of contingent consideration | -$198.9K | $716.7K |
| Effect of foreign currency remeasurement | $603.3K | $242.3K |
| Accounts receivable, non-trade | -$801.5K | $114.9K |
| Prepaid expenses | $350.4K | -$453.1K |
| Accounts payable | -$768.8K | -$917.7K |
| Accrued expenses and other current liabilities | -$2.6M | $1.5M |
| Operating lease liabilities | -$116.3K | -$123.3K |
| Deferred tax liability | -$139.2K | -$468.4K |
| Contingent consideration | -$133.1K | |
| Other non-current liabilities | -$2.9K | |
| Net cash (used in) provided by operating activities | -$12.4M | $77.2K |
| Proceeds from the sale of equity, net of subscriptions receivable and issuance costs | $17.9M | $1.5M |
| Net cash provided by financing activities | $17.9M | $1.5M |
| Effect of exchange rate on changes in cash, cash equivalents, and restricted cash | $14.0K | -$3.8K |
| Net increase in cash, cash equivalents, and restricted cash | $5.6M | $1.6M |
| Cash paid for interest expense | $3.9K | $17.4K |
| Net of subscriptions receivable | $100.0K | |
| Net of issuance costs | $600.0K | $100.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Neuphoria Therapeutics Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
- Chief executive officerSpyridon Papapetropoulos Jul 8, 2024 to now11
- PresidentSpyridon Papapetropoulos Apr 18, 2025 to now12
- Chief financial officerTimothy M. Cunningham Jul 8, 2024 to Jul 8, 202413
Board members and other officers (5)
- Board memberAaron Ngoc Dung Weaver Jul 8, 2024 to Jul 8, 202414
- Board memberAlan Fisher Jul 8, 2024 to now15
- Board memberJane Ryan Jul 8, 2024 to now16
- Board memberSpyridon Papapetropoulos Jul 8, 2024 to now11
- Board memberPeter Miles Winston Davies Jul 12, 2024 to now17
Former names
- BIONOMICS LIMITED/FISep 11, 2002 to Dec 23, 20243
Timeline
- Jul 8, 2024New chief executive Spyridon Papapetropoulos becomes CEO11
Filings
216 filings to the SEC since October 2021: 6 annual reports, 6 quarterly reports, 19 major events, 20 insider forms, 26 large holders, 139 other. The latest 20:
- Oct 5, 2026SCHEDULE 13G EDGAR
- Sep 18, 202610-K EDGAR
- Sep 18, 2026DEFA14A EDGAR
- Sep 18, 2026DEFA14A EDGAR
- Sep 18, 2026DEF 14A EDGAR
- Jul 28, 2026SCHEDULE 13G/A EDGAR
- Jul 24, 2026DEFA14A CURRENT REPORT EDGAR
- Jul 24, 20268-K CURRENT REPORT EDGAR
- May 26, 20268-K CURRENT REPORT EDGAR
- May 15, 202610-Q EDGAR
- Feb 17, 202610-Q EDGAR
- Feb 6, 2026SCHEDULE 13G/A EDGAR
- Jan 21, 20264 EDGAR
- Jan 21, 20264 EDGAR
- Jan 21, 20264 EDGAR
- Jan 21, 20264 EDGAR
- Jan 8, 20268-K CURRENT REPORT EDGAR
- Dec 29, 2025SCHEDULE 13D/A EDGAR
- Dec 18, 20258-K CURRENT REPORT EDGAR
- Dec 17, 20258-K CURRENT REPORT EDGAR
The 216 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 21, 2025 | Lynx1 Capital Management LP10% owner | Buy | 639,110 | $5.14 | $3.3M | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Coastlands Capital LPSCHEDULE 13G/A, 2 filings Nov 5, 2025 to Jul 28, 202618
- Baselake Partners, LPSCHEDULE 13G/A, 2 filings Oct 31, 2025 to Feb 6, 202619
- Lynx1 Capital Management LPSCHEDULE 13D/A, 9 filings Oct 30, 2023 to Dec 29, 202520
- Shay Capital LLCSCHEDULE 13G, 1 filing Oct 31, 202521
- ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 2 filings Nov 14, 2024 to Feb 14, 202522
- Apeiron Investment Group Ltd.SCHEDULE 13D/A, 3 filings Dec 30, 2021 to Jan 28, 202523
- BIOTECHNOLOGY VALUE FUND L PSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202424
- Point72 Asset Management, L.P.SC 13G/A, 2 filings Sep 29, 2023 to Feb 14, 202425
- TANG CAPITAL PARTNERS LPSC 13G/A, 2 filings Oct 10, 2023 to Feb 14, 202426
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARSpyridon Papapetropoulos, President
- 13
- 14SEC EDGARAaron Ngoc Dung Weaver, Board member
- 15SEC EDGARAlan Fisher, Board member
- 16SEC EDGARJane Ryan, Board member
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26